Compare American Electric Power Company Inc (AEP) vs Illumina, Inc. (ILMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Electric Power Company Inc vs Illumina, Inc. — how do they compare? American Electric Power Company Inc trades at $135.88 (market cap $74.83B), while Illumina, Inc. trades at $189.08 (market cap $29.01B). The key difference: American Electric Power Company Inc is far larger — about 2.6× Illumina, Inc.'s market cap, and American Electric Power Company Inc pays a 2.76% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AEP | ILMN | |
|---|---|---|
Market Cap | $74.83B | $29.01B |
Sector | Utilities | Health |
52-Week High | $138.69 | $194.33 |
52-Week Low | $103.96 | $91.00 |
Enterprise Value | $126.09B | $30.40B |
Dividend Yield | 2.76% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
